Market Overview:
Report Attribute | Key Statistics |
|---|---|
| Base Year | 2022 |
| Forecast Years | 2023-2033 |
| Historical Years | 2017-2022 |
Market Size in 2022 | US$ 1,993 Million |
Market Forecast in 2033 | US$ 3,994.5 Million |
Market Growth Rate (2023-2033) | 6.52% |
What is the market size of thyroid eye disease?
According to the IMARC Group, the thyroid eye disease market exhibited a market size of US$ 3,994.5 Million in the year 2033 and is projected at a CAGR of 6.52% during 2023-2033. This can be attributed to the emerging popularity of orbital electromyography (EMG) since it aids in assessing muscle involvement and detecting muscle inflammation or fibrosis.
The thyroid eye disease market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the hand eczema market.
Request for a Sample of this Report: https://www.imarcgroup.com/hand-eczema-market/requestsample
Thyroid Eye Disease Market Trends:
Thyroid eye disease is an autoimmune condition characterized by inflammation as well as swelling of the tissues around the eyes. The thyroid eye disease market has seen marked growth, propelled by several factors. A main driver of the growth is the increasing cases of the ailment. The number of thyroid disorders, especially hyperthyroidism, is climbing, resulting in a growing number of people vulnerable to thyroid eye disease. The rising patient demographic is boosting the need for TED treatments. The pharmaceutical sector has been channeling significant resources into research and the creation of innovative thyroid eye disease solutions. This encompasses new drug discoveries, gene-based medications, and specialized biologics, which promise potentially safer and more potent medicine choices. These innovations have piqued the interest of healthcare providers and the wider public.
Enhanced understanding of thyroid eye disease and its relationship with the thyroid has encouraged swifter diagnosis and treatment. Individuals are now more proactive in seeking healthcare, and such timely intervention crucially affects disease management and medication requirements. An aging demographic also propels the thyroid eye disease market. Elderly folks have a higher tendency to experience thyroid complications and, in turn, TED. As age demographics shift, the call for thyroid eye disease medicines and therapies is anticipated to escalate. However, even with advancements in research, there remains a pronounced need for efficacious and secure TED drugs. A significant number of patients find current treatments inadequate, spurring the quest for more effective solutions. This pressing demand continues to drive further exploration and ingenuity in the thyroid eye disease market arena.
Countries Covered:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country:
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the thyroid eye disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the thyroid eye disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs
This report also provides a detailed analysis of the current thyroid eye disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs:
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
Competitive Landscape of Key Players :
The competitive landscape of the thyroid eye disease market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these Key Players:
- Viridian Therapeutics
- Pierre Fabre/ACELYRIN
- HanAll Biopharma/Harbour BioMed/Immunovant
- Sling Therapeutics
Ask Analyst for Customization and Explore Full Report With TOC List of Figures: https://www.imarcgroup.com/request?type=reportid=11209flag=C
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
